



BioCore
INSTITUTE

Personalized cannabinoid-based cancer treatment

The future of cannabinoid science.

MEET THE TEAM



Jan Rožanc, PhD

Systems
pharmacology



Uroš Maver, PhD

Pharmacy



Marko Jukić, PhD

Bioinformatics



Urban Bren, PhD

Medicinal
chemistry



Marko Milojević, PhD

Biomedicine



BioCore
THERAPEUTICS



VISION AND MISSION

"Cannabinoids may cause antitumor effects by various mechanisms, including induction of cell death, inhibition of cell growth, and inhibition of tumor angiogenesis invasion and metastasis."

US National Health Institute, 2018


VISION

Establishing the **therapeutic value** of cannabinoid-based medicines in **targeting cancer**

MISSION

Develop tools for personalized **cannabinoid-based treatments**

CANNABINOIDS




BioCore
THERAPEUTICS

PROBLEM

PROBLEM / OPPORTUNITY:

- Cancer drugs are not effective
- No efficient biomarkers to detect the best patients.
- Drug companies losing money, time and the patients
- Chemotherapy is not the best therapy option for the patients, it creates inflammatory process
- Targeted therapies have adverse/harmful effect and the cancer will turn/grow back .



BioCore aims to develop:

This invention is related about development of novel biomarker candidates to enable precise tailoring of medical cannabinoid-based therapies to an individual patient's profile and cancer type. Novel cannabinoid-based cancer drug candidates will be developed in order to help drug companies to find out the best patients for their therapy to work the most efficient.

Proprietary platform employing cutting-edge AI algorithms and ML models that integrates large quantities of multi-omic profiles, environmental and lifestyle data into a high content drug sensitivity screening pipeline. Personalized models that practitioners can rely on as preventative, primary and complementary cannabinoid-based treatment options.

TRL is 2

SOLUTION

OUR SOLUTION:

FEATURES/COMPONENTS	INNOVATIVE ASPECTS	BENEFITS FOR THE DRUG COMPANY	BENEFITS FOR THE PATIENT
Novel Biomarker	Detecting more accurately	Company will be able to identify the drug will work on the patient	More successful treatment
xMAP multiplex ELISA (method)	Detecting different/more proteins in a single sample		



VALUE

VALUE PROPOSITION:

Increase treatment success



Decrease development costs

Increasing treatment success

Decreasing drug development costs

Healthy and happy patients

- Cancer treatment companies will be able to identify the drug will work on the patient
- The cancer patients will receive more successful treatment



BioCore
THERAPEUTICS

TARGETED CUSTOMER/USER SEGMENT:

- **Licensor partner:** Cancer drug development companies which are working cannabinoid-based cancer therapies and cancer diagnostic tools.
- **End User:** Late stage cancer patients


Early detection saves lives

Diagnosed in Stages I or II
Before symptoms



9 out of 10
survive 5 years
after the diagnosis

Diagnosed in Stages IV
After symptoms




1 out of 10
survive 5 years
after the diagnosis

MARKET

MARKET:

CANCER THERAPY MARKET

Revenue in USD billion, Global, 2019-2025



Resource: Mordor Intelligence



BioCore
THERAPEUTICS

MARKET

MARKET:


CANCER THERAPY MARKET

Revenue in USD billion, by Treatment Type, Global, 2017-2025

TREATMENT TYPE	2017	2018	2019	2020	2025	CAGR (%)
Chemotherapy	30.06	31.11	33.90	36.95	56.80	8.98
Targeted Therapy	31.95	33.42	36.81	40.55	65.79	10.16
Immunotherapy	22.87	23.87	26.23	28.82	46.17	9.88
Hormonal Therapy	20.13	20.61	22.23	23.98	34.99	7.85
Radiation Therapy	5.10	5.42	5.76	6.11	8.26	6.21
Other Treatment Types	17.98	18.33	19.98	21.76	33.03	8.71

CANCER THERAPY MARKET

Revenue Share (%), by Treatment Type, Global, 2019




MARKET

MARKET:


Number of biopharma medicines in development in the U.S. as of April 2019, by therapeutic category

Pharmaceuticals: biopharma medicines in development in 2019, by category



Projected cannabinoid-based pharmaceuticals market size in the U.S. from 2020 to 2029 (in billion U.S. dollars)

U.S. cannabinoid-based pharmaceuticals market size 2020-2029 projection




Resource: Statista



BioCore
THERAPEUTICS

NEXT STEPS

DEVELOPMENT ROADMAP:



BioCore
THERAPEUTICS


COMMERCIALIZATION MODEL:

- Patent Licensing
 - *Exclusive/non-exclusive*
- Patent Assignment
- Co-development for clinical trials
- Partnership for test/analysis

PATENT SCORE

PATENT SCORE:

We used patent scoring matrix to understand the the power of invention in terms of market attractiveness, technology potential and team profiles. These 3 main criteria has different sub-dimensions that can be scored according to the stage of the technology (Explore, Validate and Launch).



PATENT SCORE

PATENT SCORE:

VALIDATE Phase	
MARKET	73,3
TECHNOLOGY	38,1
TEAM	47,2
PATENT SCORE	● 159
PATENT SCORE %	● 65%

PATENT SCORE			
Investment Level	EXPLORE Phase	VALIDATE Phase	LAUNCH Phase
High Potential	>150	>180	>220
Medium Potential	120-150	150-180	180-220
Low Potential	<120	<150	<180

PATENT SCORE %			
Investment Level	EXPLORE Phase	VALIDATE Phase	LAUNCH Phase
High Potential	>%60	>%70	>%85
Medium Potential	%45-60	%60-70	%70-85
Low Potential	<%45	<%60	<%70